Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 5/20 | 0.47 |
| ▸ | NPY1R | P25929 | 4/20 | 0.47 |
| ▸ | NPY2R | P49146 | 4/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | IDE | P14735 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12464462 | 0.98 | FCER2 (0.51) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL12464461 | 0.95 | FCER2 (0.47) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL12464463 | 0.94 | FCER2 (0.52) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13952350 | 0.92 | FCER2 (0.45) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL14534320 | 0.90 | CTSC (0.51) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL12464086 | 0.90 | CTSC (0.51) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13952352 | 0.90 | FCER2 (0.52) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL12464464 | 0.86 | CTSC (0.54) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL12464088 | 0.85 | CTSC (0.53) | FCER2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13224412 | 0.83 | OPRK1 (0.47) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183358-A1 | METHODS AND COMPOSITIONS FOR DEREPRESSION OF IAP-INHIBITED CASPASE | THE BURNHAM INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | FCER2 4759/4885NPY4R 4210/4885NPY1R 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.